Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1996 Jul;74(2):258–263. doi: 10.1038/bjc.1996.348

Enhancement of anti-tumour immunity in syngeneic mice after MHC class II gene transfection.

C Mongini 1, M Sánchez Lockhart 1, C I Waldner 1, E M Alvarez 1, M J Gravisaco 1, M I Roig 1, S E Hajos 1
PMCID: PMC2074574  PMID: 8688332

Abstract

The relationship between tumorigenicity and expression of MHC class II molecules in a class II-negative murine leukaemia cell line (LBC) was studied. Analysis of structural DNA sequences encoding MHC class II proteins was performed by Southern blot with DNA isolated from both the original LB tumour and LBC cell line, digested with EcoRI, BamHI and HindIII and hybridised with specific probes for I-A alpha d and I-A beta d chains. Similar patterns were obtained for LB, LBC and normal BALB/c lymphocytes. In vitro treatment with IFN-gamma (20 - 1000 IU ml-1) failed to induce the expression of MHC class II antigens in LBC cell line. LBC cells were tri-transfected by a liposome-mediated protocol with I-A alpha d, I-A beta d genes and pSV2neo. Cells were selected for growth in medium containing Geneticin (G418). Surviving transfectants were cloned and three I-A+ clones were obtained after 20 days (LBCT cells). Syngeneic mice inoculated with 1.0 x 10(3) LBCT (I-A+) cells failed to develop a tumour, whereas the DT50 of mice injected with 1.0 x 10(6) LBCT cells was three times the value for mice injected with LBC cells (I-A-). Furthermore, specific CTL response against tumour cells was significantly enhanced upon priming with irradiated LBC-transfected cells (27 +/- 2%) compared with irradiated LBC cells (15 +/- 1.5%) in a 4 h 51Cr-release assay. It is suggested that neoexpression of MHC class II molecules enhances anti-tumour response by transforming tumour cells into professional antigen-presenting cells (APCs), which may be used to improve tumour-specific immunity in the autologous host.

Full text

PDF
258

Images in this article

260Figure 1
on p.260

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baskar S., Azarenko V., Garcia Marshall E., Hughes E., Ostrand-Rosenberg S. MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice. Cell Immunol. 1994 Apr 15;155(1):123–133. doi: 10.1006/cimm.1994.1106. [DOI] [PubMed] [Google Scholar]
  2. Baskar S., Glimcher L., Nabavi N., Jones R. T., Ostrand-Rosenberg S. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J Exp Med. 1995 Feb 1;181(2):619–629. doi: 10.1084/jem.181.2.619. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bottazzo G. F., Dean B. M., McNally J. M., MacKay E. H., Swift P. G., Gamble D. R. In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulitis. N Engl J Med. 1985 Aug 8;313(6):353–360. doi: 10.1056/NEJM198508083130604. [DOI] [PubMed] [Google Scholar]
  4. Burnet F. M. The concept of immunological surveillance. Prog Exp Tumor Res. 1970;13:1–27. doi: 10.1159/000386035. [DOI] [PubMed] [Google Scholar]
  5. Fearon E. R., Pardoll D. M., Itaya T., Golumbek P., Levitsky H. I., Simons J. W., Karasuyama H., Vogelstein B., Frost P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell. 1990 Feb 9;60(3):397–403. doi: 10.1016/0092-8674(90)90591-2. [DOI] [PubMed] [Google Scholar]
  6. Fuji H., Iribe H. Clonal variation in tumorigenicity of L1210 lymphoma cells: nontumorigenic variants with an enhanced expression of tumor-associated antigen and Ia antigens. Cancer Res. 1986 Nov;46(11):5541–5547. [PubMed] [Google Scholar]
  7. Glimcher L. H., Kara C. J. Sequences and factors: a guide to MHC class-II transcription. Annu Rev Immunol. 1992;10:13–49. doi: 10.1146/annurev.iy.10.040192.000305. [DOI] [PubMed] [Google Scholar]
  8. Golumbek P. T., Lazenby A. J., Levitsky H. I., Jaffee L. M., Karasuyama H., Baker M., Pardoll D. M. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science. 1991 Nov 1;254(5032):713–716. doi: 10.1126/science.1948050. [DOI] [PubMed] [Google Scholar]
  9. Gross-Bellard M., Oudet P., Chambon P. Isolation of high-molecular-weight DNA from mammalian cells. Eur J Biochem. 1973 Jul 2;36(1):32–38. doi: 10.1111/j.1432-1033.1973.tb02881.x. [DOI] [PubMed] [Google Scholar]
  10. Hämmerling G. J., Klar D., Pülm W., Momburg F., Moldenhauer G. The influence of major histocompatibility complex class I antigens on tumor growth and metastasis. Biochim Biophys Acta. 1987 Nov 25;907(3):245–259. doi: 10.1016/0304-419x(87)90008-4. [DOI] [PubMed] [Google Scholar]
  11. Jacobson S., Richert J. R., Biddison W. E., Satinsky A., Hartzman R. J., McFarland H. F. Measles virus-specific T4+ human cytotoxic T cell clones are restricted by class II HLA antigens. J Immunol. 1984 Aug;133(2):754–757. [PubMed] [Google Scholar]
  12. James R. F., Edwards S., Hui K. M., Bassett P. D., Grosveld F. The effect of class II gene transfection on the tumourigenicity of the H-2K-negative mouse leukaemia cell line K36.16. Immunology. 1991 Feb;72(2):213–218. [PMC free article] [PubMed] [Google Scholar]
  13. Kappler J. W., Skidmore B., White J., Marrack P. Antigen-inducible, H-2-restricted, interleukin-2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition. J Exp Med. 1981 May 1;153(5):1198–1214. doi: 10.1084/jem.153.5.1198. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Kern D. E., Klarnet J. P., Jensen M. C., Greenberg P. D. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. J Immunol. 1986 Jun 1;136(11):4303–4310. [PubMed] [Google Scholar]
  15. Londei M., Lamb J. R., Bottazzo G. F., Feldmann M. Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells. Nature. 1984 Dec 13;312(5995):639–641. doi: 10.1038/312639a0. [DOI] [PubMed] [Google Scholar]
  16. Lugasi H., Hajos S., Murphy J. R., Strom T. B., Nichols J., Peñarroja C., Naor D. Murine spontaneous T-cell leukemia constitutively expressing IL-2 receptor--a model for human T-cell malignancies expressing IL-2 receptor. Int J Cancer. 1990 Jan 15;45(1):163–167. doi: 10.1002/ijc.2910450129. [DOI] [PubMed] [Google Scholar]
  17. McKisic M. D., Sant A. J., Fitch F. W. Some cloned murine CD4+ T cells recognize H-2Ld class I MHC determinants directly. Other cloned CD4+ T cells recognize H-2Ld class I MHC determinants in the context of class II MHC molecules. J Immunol. 1991 Nov 1;147(9):2868–2874. [PubMed] [Google Scholar]
  18. Mongini C., Waldner C. I., Alvarez E., Roig M. I., Sánchez Lockhart M., Gravisaco M. J., Hajos S. E. Induction of anti-tumour immunity in syngeneic mice by a leukaemic cell line. Scand J Immunol. 1995 Mar;41(3):298–304. doi: 10.1111/j.1365-3083.1995.tb03568.x. [DOI] [PubMed] [Google Scholar]
  19. Mongini C., Waldner C., Roig I., Hajos S. E. Murine T cell leukemia line in suspension culture. In Vitro Cell Dev Biol. 1991 Jul;27A(7):523–524. doi: 10.1007/BF02631281. [DOI] [PubMed] [Google Scholar]
  20. Moudgil K. D., Sercarz E. E. Can antitumor immune responses discriminate between self and nonself? Immunol Today. 1994 Aug;15(8):353–355. doi: 10.1016/0167-5699(94)90172-4. [DOI] [PubMed] [Google Scholar]
  21. Ostrand-Rosenberg S., Thakur A., Clements V. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol. 1990 May 15;144(10):4068–4071. [PubMed] [Google Scholar]
  22. Pardoll D. M. Cancer vaccines. Immunol Today. 1993 Jun;14(6):310–316. doi: 10.1016/0167-5699(93)90051-L. [DOI] [PubMed] [Google Scholar]
  23. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Steinmetz M., Malissen M., Hood L., Orn A., Maki R. A., Dastoornikoo G. R., Stephan D., Gibb E., Romaniuk R. Tracts of high or low sequence divergence in the mouse major histocompatibility complex. EMBO J. 1984 Dec 1;3(12):2995–3003. doi: 10.1002/j.1460-2075.1984.tb02246.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Steinmetz M., Minard K., Horvath S., McNicholas J., Srelinger J., Wake C., Long E., Mach B., Hood L. A molecular map of the immune response region from the major histocompatibility complex of the mouse. Nature. 1982 Nov 4;300(5887):35–42. doi: 10.1038/300035a0. [DOI] [PubMed] [Google Scholar]
  26. Tanaka K., Yoshioka T., Bieberich C., Jay G. Role of the major histocompatibility complex class I antigens in tumor growth and metastasis. Annu Rev Immunol. 1988;6:359–380. doi: 10.1146/annurev.iy.06.040188.002043. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES